Strides Pharma Science Balance Sheet Health
Financial Health criteria checks 3/6
Strides Pharma Science has a total shareholder equity of ₹22.1B and total debt of ₹22.2B, which brings its debt-to-equity ratio to 100%. Its total assets and total liabilities are ₹59.9B and ₹37.7B respectively. Strides Pharma Science's EBIT is ₹6.7B making its interest coverage ratio 2.7. It has cash and short-term investments of ₹2.5B.
Key information
100.0%
Debt to equity ratio
₹22.15b
Debt
| Interest coverage ratio | 2.7x |
| Cash | ₹2.47b |
| Equity | ₹22.15b |
| Total liabilities | ₹37.75b |
| Total assets | ₹59.90b |
Recent financial health updates
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Financial Position Analysis
Short Term Liabilities: STAR's short term assets (₹30.9B) exceed its short term liabilities (₹29.6B).
Long Term Liabilities: STAR's short term assets (₹30.9B) exceed its long term liabilities (₹8.1B).
Debt to Equity History and Analysis
Debt Level: STAR's net debt to equity ratio (88.9%) is considered high.
Reducing Debt: STAR's debt to equity ratio has increased from 67.5% to 100% over the past 5 years.
Debt Coverage: STAR's debt is well covered by operating cash flow (36.9%).
Interest Coverage: STAR's interest payments on its debt are not well covered by EBIT (2.7x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 03:41 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Strides Pharma Science Limited is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |